Are PMCB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PMCB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / PMCB / insiders

LIMN (35) CRIS (27) CLDI (31) BTTC (38) ⌘ Pro Terminal →

PharmaCyte Biotech Inc. (PMCB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.31 +2.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.31

PharmaCyte Biotech Inc. (PMCB) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PMCB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PMCB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, PharmaCyte Biotech Inc. (NASDAQ: PMCB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.31 (+2.71% 1D, market cap $3.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PMCB ranks #663 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PMCB compare to LIMN and CRIS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PMCB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.2%. By comparison, LIMN (Liminatus Pharma Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, PMCB leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PMCB?

▼

Per PMCB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001157075), PharmaCyte Biotech Inc. generated $19.2M in revenue (+56.6% YoY), -$19.4M in net income, and -$5.2M in free cash flow against $55.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.31 (+0.30%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PMCB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY PMCB SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 32.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.36-5.6% Next Q

Q2 (-2Q)

Grade E$0.34+0% Next Q

Q3 (-1Q)

Grade E$0.34-8.8% Next Q

Current

Grade E$0.31-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PMCB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PMCB currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.41) and Max Pain ($0.33) forces dealer call-delta covering toward $1.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PMCB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PMCB Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PMCB Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PMCB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PMCB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PMCB)

✓Walkthrough of PMCB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PMCB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.21%▼ DESCENDING CHANNEL

2026-11-03O $0.33H $0.33L $0.30C $0.31VOL 121.7K

RES: $0.38SUP: $0.16SMA50: $0.41SMA200: $0.64

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PMCB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PMCB Butterfly Map → + Track PMCB →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +56.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PMCB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PMCB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PMCB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PMCB)

Health Care Rank #663 of 1015 ⚔️ LIMN vs PMCB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PMCB vs. LIMN, CRIS, CLDI, BTTC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, PharmaCyte Biotech Inc. (PMCB) ranks #663 by composite RQD confidence (34/100, grade E) and #971 by equity capitalization ($3.2M). Within this direct 5-issuer industry benchmark cohort, PMCB leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with PMCB at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PMCB ACTIVE PharmaCyte Biotech Inc.	E	34/100	—	—	-30.2%	+2.71%	$3.2M	Benchmark Subject
LIMN Liminatus Pharma Inc. (Class A)	D-	35/100	—	—	-35.0%	-10.64%	$3.8M	/limn-vs-pmcb →
CRIS Curis Inc.	E	27/100	—	—	-35.0%	+10.17%	$4.0M	/cris-vs-pmcb →
CLDI Calidi Biotherapeutics Inc.	E	31/100	—	—	-35.0%	-4.36%	$2.5M	/cldi-vs-pmcb →
BTTC Black Titan Corporation	D-	38/100	—	—	—	-3.17%	$4.8M	/bttc-vs-pmcb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001157075 ↗

In its most recent audited fiscal period (FY2025, filed 2026-04-30), PharmaCyte Biotech Inc. (PMCB) reported GAAP revenue of $19.2M (+56.6% vs. FY2024 revenue of $12.3M , and -19.6% cumulative change since FY2023) , GAAP net income of -$19.4M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (-73.0% YoY). On the balance sheet, PMCB closed FY2025 with $55.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-04-30	$19.2M	-$19.4M	-$5.2M	-$5.2M	$55.9M	—
FY2024 (FY)	2025-04-30	$12.3M	$30.7M	-$3.0M	-$3.0M	$43.8M	—
FY2023 (FY)	2024-04-30	$23.9M	$333.8K	-$2.2M	-$2.2M	—	—

3. PMCB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PMCB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PMCB compare to LIMN and CRIS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PMCB?

Where is PMCB trading relative to its 50-day, 200-day, and 52-week technical levels?

PMCB last traded at $0.31 (+2.71% on volume of 40,845 shares), positioning the stock -24.39% below its 50-day simple moving average ($0.41) and -51.56% below its 200-day simple moving average ($0.64). Across its 52-week range of $0.30 to $1.51, PMCB sits at the 0.8% percentile with a 14-day RSI of 32.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.35).

Direct Sub-Reports: PMCB RQD Cockpit PMCB 12M Forecast PMCB Earnings & Move PMCB Dividends & DRIP PMCB Insiders & 13F PMCB Whale Options PMCB Profit Sankey PMCB News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

PMCB — PharmaCyte Biotech Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2026-04-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

PharmaCyte Biotech Inc. (PMCB) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.31 (+2.71% 1D, market capitalization $3.2M).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -30.2%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

PharmaCyte Biotech Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances), per the SEC profile. Reported revenue is — in each listed period, . — for how the company makes money.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-04-30), PharmaCyte Biotech Inc. (PMCB) reported $19.2M in annual revenue (up from $12.3M in FY2024, +56.6% YoY) and -$19.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($23.9M revenue, $333.8K net income) through FY2025, PMCB scaled operating cash flow to -$5.2M and free cash flow to -$5.2M, backed by $55.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.30 – $1.51 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), PMCB carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: Can PMCB sustain or expand its — operating margin and -30.2% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $19.2M and free cash flow of -$5.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is PMCB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PMCB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PharmaCyte Biotech Inc. (PMCB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PMCB Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 20h ago

PharmaCyte Biotech, Inc. Estimates – NASDAQ:PMCB

TradingView report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 23h ago

PharmaCyte Biotech (PMCB) Ticks Up 5.45% to $0.36 as Micro-Cap Presses Against Resistance - AD Line Divergence

https://www.siam.in/ report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Top U.S. Stock Losers: Biggest Price Declines

TradingKey report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

ICICI Bank (IBN) Trades Nearly Flat at $27.89, Boxed Between $26.50 Support and $29.28 Resistance - Strangle Setup

https://www.siam.in/ report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

PharmaCyte Biotech, Inc. (PMCB) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

PharmaCyte Biotech, Inc. Stock Price Today | PMCB Live Chart & News

Traders Union report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Live PharmaCyte Biotech, Inc. (PMCB) Technical Analysis

Traders Union report covering PharmaCyte Biotech Inc. (PMCB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PMCB Bull vs. Bear Conversation Board — What's Your Call at $0.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PMCB 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $0.39 (+30.0%)

📌 Pinned Debate

Shares trade near $0.33 with institutional accumulation and options positioning scored at 10 of 20 in the RQD rating.

The street is overcomplicating PharmaCyte Biotech Inc. (PMCB). Shares trade near $0.33 with institutional accumulation and options positioning scored at 10 of 20 in the RQD rating.. With an RQD score of 34/100 (E) and Forensic Balance Sheet at 7/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.32.

RetailWhale_TX 🐂 BULL

@FadeTheHype Shorting a 9/20 institutional whale-flow stock at $0.30 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.25 (-16.7%)

Spot @ $0.30

Zero revenue, -30.2% ROIC, and an Altman Z-Score of 0.2 signal a business consuming capital with high distress risk.

I respect the product at PharmaCyte Biotech Inc., but the stock at $0.30 is a different story. Zero revenue, -30.2% ROIC, and an Altman Z-Score of 0.2 signal a business consuming capital with high distress risk.. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?